United-Guardian Q1 Sales Up 16% to $2.87M, Earnings Rise 46%
UG•United-Guardian’s Q1 sales rose 15.7% to $2,872,222 while net income jumped 46% to $818,902 ($0.18 per share). Pharmaceutical revenue grew 24% on higher Renacidin demand, cosmetic ingredient sales climbed 21% with Ashland Specialty Ingredients boosting orders by 45%, and a $303,133 settlement added to income.
1. First Quarter Financial Results
Sales increased from $2,481,127 to $2,872,222 in Q1 2026, a 15.7% gain, and net income rose from $560,895 to $818,902, translating to EPS of $0.18 versus $0.12 a year ago.
2. Segment Performance
Pharmaceutical division revenue surged 24% driven by higher Renacidin demand, while cosmetic ingredient sales climbed 21%, reflecting a rebound in orders from Ashland Specialty Ingredients that rose 45% year-over-year.
3. Settlement Income
The company recognized $303,133 in settlement income related to a contract manufacturer shutdown in late 2023, bolstering other income for the quarter.
4. Outlook and Growth Initiatives
United-Guardian expects continued sales expansion through new distribution agreements, increased focus on natural product lines, and expanded outreach and market penetration for Renacidin.
